• Explore /
  • Poster
  • / Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.

Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.

Abstract Video & Slides Poster

Authors

null

Efstathios Kastritis

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Efstathios Kastritis , Angela Dispenzieri , Ashutosh D. Wechalekar , Stefan O. Schönland , Kihyun Kim , Vaishali Sanchorawala , Heather Jolie Landau , Fiona Kwok , Kenshi Suzuki , Ray Comenzo , Giovanni Palladini , Deborah Berg , Guohui Liu , Arun Kumar , Douglas V. Faller , Giampaolo Merlini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Plasma Cell Disorders

Clinical Trial Registration Number

NCT01659658

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8546)

DOI

10.1200/JCO.2020.38.15_suppl.8546

Abstract #

8546

Poster Bd #

446

Abstract Disclosures

Similar Posters

First Author: James R. Berenson

First Author: Andrew J Yee

First Author: Charlotte Pawlyn

First Author: Shaji Kumar